Sutro Biopharma (STRO) Price & Analysis

Compare

710 Followers

STRO Stock Chart & Stats

$0.82

-$0.05(-2.48%)

At close: Jan 08 4:00 PM EST

$0.82

-$0.05(-2.48%)

Day’s Range― - ―

52-Week Range$0.52 - $4.60

Previous CloseN/A

Volume326.60K

Average Volume (3M)987.85K

Market Cap

$86.47M

Enterprise Value$74.93M

Total Cash (Recent Filing)$167.59M

Total Debt (Recent Filing)$17.66M

Price to Earnings (P/E)―

Beta3.82

Next Earnings

Mar 12, 2026

EPS Estimate

-0.4

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.67

Shares Outstanding84,774,180

10 Day Avg. Volume2,002,360

30 Day Avg. Volume987,852

Financial Highlights & Ratios

PEG Ratio>-0.01

Price to Book (P/B)3.17

Price to Sales (P/S)2.28

P/FCF Ratio-0.73

Enterprise Value/Market Cap0.87

Enterprise Value/Revenue0.71

Enterprise Value/Gross Profit0.81

Enterprise Value/Ebitda-0.44

Forecast

1Y Price Target

$2.36

Price Target Upside187.80% Upside

Rating ConsensusModerate Buy

Number of Analyst Covering8

EPS Forecast (FY)N/A

Revenue Forecast (FY)N/A

Bulls Say, Bears Say

Bulls Say

Collaborations And PartnershipsCollaboration with Astellas to develop immunostimulatory ADCs has advanced one candidate into IND enabling studies and represents a potential path to additional external funding if successful.

Preclinical And Clinical DevelopmentProof-of-concept animal data for STRO 006 demonstrates consistent tumor control at clinically relevant doses and a clean tolerability profile.

Regulatory ProgressThe FDA has cleared the IND for STRO-004 and the company aims to dose the first patient in the Phase I.

Bears Say

Early Stage Pipeline RiskSutro’s pipeline is still early, and the company is seen as a longer term opportunity for investors who are comfortable underwriting preclinical and early clinical risk.

Funding And Financial ViabilityThe company may need additional capital in 2026 to ensure it reaches Phase 1 data with enough cash.

Safety And Efficacy ConcernsPast safety challenges with TF-targeted ADCs raise questions about whether the DAR8 exatecan format can achieve a clinically acceptable therapeutic index.

Sutro Biopharma News

Sutro Biopharma Reports Q3 2025 Financial Results

Sutro Biopharma ( ($STRO) ) has released its Q3 earnings. Here is a breakdown of the information Sutro...

1d ago

STRO

Sutro Biopharma Announces Major Organizational Restructuring

Sutro Biopharma ( ($STRO) ) has shared an update. On September 29, 2025, Sutro Biopharma announced an organizational...

1M ago

STRO

Sutro Biopharma announces restructuring, workforce reduction of about 33%

Sutro Biopharma (STRO) announced an organizational restructuring to prioritize the advancement of its three ADC programs and research...

1M ago

STRO

Sutro Biopharma price target lowered to $4 from $7 at Jefferies

Jefferies lowered the firm’s price target on Sutro Biopharma (STRO) to $4 from $7 and keeps a Buy...

2M ago

STRO

Sutro Biopharma’s STRO-002: A Promising Phase 1 Trial Update in Ovarian and Endometrial Cancers

Sutro Biopharma (($STRO)) announced an update on their ongoing clinical study. Sutro Biopharma’s recent clinical study update focuses...

3M ago

STRO

Sutro Biopharma price target lowered to $3 from $4 at Wells Fargo

Wells Fargo lowered the firm’s price target on Sutro Biopharma (STRO) to $3 from $4 and keeps an...

3M ago

STRO

Sutro Biopharma’s Strategic Shift and Pipeline Developments: A Hold Rating Amid Transitional Phase

Andres Y. Maldonado, an analyst from H.C. Wainwright, reiterated the Hold rating on Sutro Biopharma. The associated price...

3M ago

STRO

Sutro Biopharma Advances ADC Pipeline and Reports Q2 2025 Results

Sutro Biopharma ( ($STRO) ) has released its Q2 earnings. Here is a breakdown of the information Sutro...

3M ago

STRO

Sutro Biopharma enters research collaboration with FDA for ADC standards

Sutro Biopharma (STRO) entered into a collaboration with the U.S. Food and Drug Administration to develop reference materials...

4M ago

STRO

Sutro Biopharma Faces NASDAQ Non-Compliance Notice

Sutro Biopharma ( ($STRO) ) has provided an announcement. On June 20, 2025, Sutro Biopharma received a notice...

5M ago

STRO

Sutro, Sarepta, Incyte, Signet, Wix: Trending by Analysts

Analysts are intrested in these 5 stocks: ( ($STRO) ), ( ($SRPT) ), ( ($INCY) ), ( ($SIG)...

5M ago

SIG

WIX

Piper upgrades Sutro Biopharma to Overweight on attractive valuation

Piper Sandler last night upgraded Sutro Biopharma (STRO) to Overweight from Neutral with an unchanged price target of...

5M ago

STRO

Sutro Biopharma upgraded to Overweight from Neutral at Piper Sandler

Piper Sandler upgraded Sutro Biopharma (STRO) to Overweight from Neutral with an unchanged price target of $2. Published...

5M ago

STRO

Sutro Biopharma Adopts Key Proposals at Annual Meeting

Sutro Biopharma ( ($STRO) ) just unveiled an announcement. On June 6, 2025, Sutro Biopharma held its 2025...

5M ago

STRO

STRO FAQ

What was Sutro Biopharma Inc’s price range in the past 12 months?

Sutro Biopharma Inc lowest stock price was $0.52 and its highest was $4.60 in the past 12 months.

What is Sutro Biopharma Inc’s market cap?

Sutro Biopharma Inc’s market cap is $86.47M.

When is Sutro Biopharma Inc’s upcoming earnings report date?

Sutro Biopharma Inc’s upcoming earnings report date is Mar 12, 2026 which is in 124 days.

How were Sutro Biopharma Inc’s earnings last quarter?

Sutro Biopharma Inc released its earnings results on Nov 06, 2025. The company reported -$0.67 earnings per share for the quarter, missing the consensus estimate of -$0.394 by -$0.276.

Is Sutro Biopharma Inc overvalued?

According to Wall Street analysts Sutro Biopharma Inc’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Sutro Biopharma Inc pay dividends?

Sutro Biopharma Inc does not currently pay dividends.

What is Sutro Biopharma Inc’s EPS estimate?

Sutro Biopharma Inc’s EPS estimate is -0.4.

How many shares outstanding does Sutro Biopharma Inc have?

Sutro Biopharma Inc has 84,774,180 shares outstanding.

What happened to Sutro Biopharma Inc’s price movement after its last earnings report?

Sutro Biopharma Inc reported an EPS of -$0.67 in its last earnings report, missing expectations of -$0.394. Following the earnings report the stock price went down -4.268%.

Which hedge fund is a major shareholder of Sutro Biopharma Inc?

Currently, no hedge funds are holding shares in STRO

Sutro Biopharma Stock Smart Score

Neutral

Fundamentals

Return on Equity

-347.64%

Trailing 12-Months

Asset Growth

-46.35%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Sutro Biopharma Inc

Sutro Biopharma, Inc. is a biotechnology company focused on the development and commercialization of therapeutics for cancer and other serious diseases. Utilizing its proprietary cell-free protein synthesis platform, Sutro Biopharma designs and produces next-generation protein therapeutics such as antibody-drug conjugates (ADCs) and bispecific antibodies. The company's innovative approach allows for the rapid development of complex biologics, targeting various therapeutic areas, particularly in oncology.

Sutro Biopharma (STRO) Earnings & Revenues

Historic Earnings Reports

STRO Stock 12 Month Forecast

Average Price Target

$2.36

▲(187.80% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"2":"$2","5":"$5","-1":"-$1","0.5":"$0.5","3.5":"$3.5"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":4,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$4.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":2.36,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$2.36</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":0.8,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$0.80</span>\n  </div></div>","useHTML":true}}],"tickPositions":[-1,0.5,2,3.5,5],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Jan<br/>2025","6":"May<br/>2025","9":"Aug<br/>2025","12":"Nov<br/>2025","25":"Nov<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1.12,1.3415384615384616,1.563076923076923,1.7846153846153847,2.006153846153846,2.2276923076923074,2.4492307692307693,2.670769230769231,2.8923076923076922,3.1138461538461537,3.335384615384615,3.5569230769230766,3.7784615384615385,{"y":4,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1.12,1.2153846153846155,1.310769230769231,1.4061538461538463,1.5015384615384617,1.5969230769230771,1.6923076923076923,1.7876923076923077,1.883076923076923,1.9784615384615385,2.073846153846154,2.1692307692307695,2.2646153846153845,{"y":2.36,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1.12,1.0953846153846154,1.070769230769231,1.0461538461538462,1.0215384615384617,0.996923076923077,0.9723076923076924,0.9476923076923078,0.9230769230769231,0.8984615384615385,0.8738461538461539,0.8492307692307692,0.8246153846153847,{"y":0.8,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":3.5,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 20,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.55,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 19,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.75,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 19,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.84,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.59,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 11, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.595,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 13, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.07,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 18, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.904,"date":1748736000000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 13, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 5</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":0.68,"date":1751328000000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 6</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":0.81,"date":1754006400000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 7</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":0.951,"date":1756684800000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 4</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":0.903,"date":1759276800000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 4</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":1.12,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >